BIOMAT Database Logo BIOMAT Database Logo

[Combination chemotherapy of cyclophosphamide, adriamycin and cisplatin in advanced urothelial cancer]. 1987

S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
Dept. of Urology, Kyoto Prefectural University of Medicine.

Sixteen patients with advanced evaluable urothelial cancer were treated with a chemotherapy regimen of cyclophosphamide, adriamycin and cisplatin (CAP). Cisplatin 50 mg/m2 and adriamycin 30 mg/m2 were given on the first day and cyclophosphamide 200 mg/m2 was given from the second to the fifth day. This course was repeated every 3 weeks. The objective response rate was 25% (4 of 16 patients), with 1 patient achieving complete remission. The survival time of responders was longer than that of nonresponders, although the difference was not significant (generalized Wilcoxon method). As side effects, nausea with vomiting (43.8%), renal dysfunction (6.3%), anemia (12.5%), leucopenia (12.5%), thrombocytopenia (25.0%), alopecia (68.8%), heart failure (6.3%) and peripheral neuropathy (6.3%) were noticed. One patient died of sepsis due to agranulocytosis and another died suddenly of heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy)].
February 1987, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
July 1991, Hinyokika kiyo. Acta urologica Japonica,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
July 1975, Cancer,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
February 1989, Gan no rinsho. Japan journal of cancer clinics,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
[Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
August 1988, Hinyokika kiyo. Acta urologica Japonica,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study.
January 1982, European journal of cancer & clinical oncology,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(II) combination chemotherapy in patients with advanced cancer.
August 1977, Cancer treatment reports,
S Nakagawa, and M Nakao, and K Toyoda, and M Nukui, and H Takada, and K Ebisui, and H Watanabe, and T Furusawa, and M Maegawa, and H Kaiho
Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
January 1987, European journal of gynaecological oncology,
Copied contents to your clipboard!